In a given clinical trial comparing prasugrel with clopidogrel in patients with acute coronary syndrome, the authors reported the following results: "The primary efficacy end point occurred in 10.5% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio(HR) for prasugrel vs. clopidogrel, 0.81;95% confidence interval [CI],0.73 TO 0.90). In the prasugrel group the rates of myocardial infarction (9.7% for clopidogrel vs 7.4% for prasugrel, P<0.001), urgent target-vessel revascularization (3.7% vs 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs 0.9%), including non-fatal bleeding (1.1% vs 0.9%; hazard ratio, 1.25; P=0.001) and fatal bleeding (0.4% vs 0.1%). "In the trial above, what is the number of people needed to treat with prasugrel to decrease the primary efficacy measure in one patient?